Class I Phosphatidylinositol 3-Kinases
"Class I Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits.
| Descriptor ID |
D058534
|
| MeSH Number(s) |
D08.811.913.696.620.500.100.100 D08.811.913.696.620.500.200.100 D12.776.476.162
|
| Concept/Terms |
Class I Phosphatidylinositol 3-Kinases- Class I Phosphatidylinositol 3-Kinases
- Class I Phosphatidylinositol 3 Kinases
- Class I Phosphatidylinositol 3-Kinase
- Class I Phosphatidylinositol 3 Kinase
- Phosphatidylinositol 3-Kinase, Class I
- Phosphatidylinositol 3 Kinase, Class I
|
Below are MeSH descriptors whose meaning is more general than "Class I Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Class I Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Class I Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Class I Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 4 | 4 | 8 |
| 2018 | 4 | 2 | 6 |
| 2019 | 0 | 4 | 4 |
| 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Class I Phosphatidylinositol 3-Kinases" by people in Profiles.
-
PI3Kd Inhibition as a Potential Therapeutic Target in COVID-19. Front Immunol. 2020; 11:2094.
-
Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for Unexpected "Vertigo". Int J Gynecol Pathol. 2020 Jan; 39(1):68-71.
-
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA. Gene. 2019 Oct 05; 715:143995.
-
Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. Hum Pathol. 2019 10; 92:10-17.
-
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019 06; 153(3):535-540.
-
The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019 May 25; 698:120-128.
-
Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene. Ital J Pediatr. 2018 Sep 19; 44(1):110.
-
Primary immunodeficiency disorder caused by phosphoinositide 3-kinase d deficiency. J Allergy Clin Immunol. 2018 11; 142(5):1650-1653.e2.
-
CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome. Immunol Cell Biol. 2018 11; 96(10):1060-1071.
-
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase d Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase d Syndrome Registry. Front Immunol. 2018; 9:543.